Mini Review
Published on 01 Apr 2021
Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
in Immunological Tolerance and Regulation
Frontiers in Immunology
doi 10.3389/fimmu.2021.648408
- 40,566 views
- 153 citations
7 articles related to "Low Dose Il 2 Therapy"
Articles
Review
Published on 12 Sep 2023
Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2023.1230264
- 13,083 views
- 26 citations
Brief Research Report
Published on 18 Dec 2019
Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2019.01490
- 6,598 views
- 15 citations
Original Research
Published on 29 Nov 2022
Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial
in Autoimmune and Autoinflammatory Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2022.947341
- 8,193 views
- 23 citations
Original Research
Published on 02 Aug 2022
Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation
in T Cell Biology
Frontiers in Immunology
doi 10.3389/fimmu.2022.891925
- 7,622 views
- 10 citations
Original Research
Published on 06 Feb 2025
The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2025.1522893
- 4,285 views
- 2 citations
Systematic Review
Published on 17 Oct 2024
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Frontiers in Immunology
doi 10.3389/fimmu.2024.1425478
- 8,853 views